Prothrombin time (PT) is the primary assay used in monitoring oral anticoagulant therapy. The prolongation of PT depends on reductions in three of the vitamin K dependent clotting factors (II, VII and IX). Changes in the PT noted in the first few days of vitamin K antagonist (VKA) therapy are primarily due to reductions in factors VII and IX, which have the shortest half-lives (6 and 24 hours, respectively).
Either venous or capillary blood can be used to monitor anticoagulation therapy.
To produce a result, thromboplastin is added to the blood sample to activate coagulation. This causes a blood clot to form. The time it takes for this clot to form is measured in seconds and is known as the PT.
In most countries, blood coagulability is typically expressed in a unit known as the Quick value. In this case the measured PT is expressed in relation to the coagulation time of a healthy person. The value obtained is the percentage of the standard value. In a person not receiving oral anticoagulation the normal Quick value is between 70 and 100%.
A Quick value of only 30%, for instance, indicates that the blood coagulation time is longer than normal.
The longer the patient's coagulation time, the lower the Quick value.
Quick values measured with different thromboplastins cannot be directly compared with one another, as for instance sensitivity to clotting factors may differ. To render coagulation times as comparable as possible, the World Health Organization (WHO) approved in 1983 a standard reference thromboplastin. Every manufacturer of thromboplastin must calibrate his reagent against the WHO standard (2 references exist: one for human recombinant based thromboplastins, one for rabbit brain based ones). The value obtained is known as the International Sensitivity Index (ISI). This enables the various sensitivities of the thromboplastins to be ascertained and it will be used to calculate the INR.
WHO recommends ISI to be < 1.7. In many countries, a low (1.0) ISI is favored.
The INR is a standardization method that attempts to minimize differences between thromboplastin reagents through a calibration process in which all commercial thromboplastins are compared with an International Reference Preparation (IRP) maintained by the World Health Organization (WHO).
The INR method is not perfect in correcting for differences between different laboratories utilizing different thromboplastin reagents, but it does reduce the variation between different laboratories and provides clinically useful results. To minimize this variation, each monitoring site should use results from only one type of instrument and thromboblastin reagent origin for each patient.
Mean normal PT (MNPT) is the geometric mean PT of minimum 20 healthy subjects in a defined laboratory population.
For example: The PT of a patient receiving oral anticoagulant is 64 seconds (= 18% Quick). The prothrombin time of a normal plasma is 22 seconds (= 100% Quick). The ISI of the thromboplastin used is 0.93. Substituting this value in the formula gives the following INR:
(64) / (22) 0.93 = 2.7 INR
This signifies a coagulation time that is 2.7 times longer than the standard.
The longer the patient's coagulation time, the higher the INR.
"Every 9 or 10 days I open my kit, draw a drop of blood from my finger and within 10 seconds I know what my INR is"
"An instant result was just magic. Absolute magic."
Add text here
Our promise to ensure we deliver the highest quality standards to our patients and customers, now and in the future.
Understand more about prothrombin time and INR value to monitor a patient's response to anticoagulants.
What medical conditions benefit from VKA therapy and INR monitoring?
A brief overview of available oral anticoagulants and considerations for their use.
Learn more about the world class training and support that we offer you and your patients.
